美国心脏协会PREVENT方程的开发与验证
研究基于25个数据集开发并外部验证了美国心脏协会PREVENT方程,用于预测30至79岁无心血管病成人的心血管病风险。
要点
- PREVENT方程预测心血管病风险的外部验证C统计量女性0.794、男性0.757。
- 方程性别特异、无种族项,调整非心血管病死亡竞争风险。
- 加入尿白蛋白肌酐比等指标可小幅提升区分度,明显改善白蛋白尿者校准。
核心结论
- PREVENT方程利用常规临床变量可准确预测美国成人新发心血管病及亚型风险。
研究设计与样本
- 研究对象为30至79岁无已知心血管病的美国成人。
主要发现
- 外部验证中总心血管病C统计量女性0.794(四分位区间0.763-0.809)、男性0.757(0.727-0.778)。
- 校准斜率女性1.03(0.81-1.16)、男性0.94(0.81-1.13)。
- 加入尿白蛋白肌酐比、糖化血红蛋白和社会剥夺指数后区分度提升幅度小但统计学显著,ΔC统计量女性0.004(0.004-0.005)、男性0.005(0.004-0.007)。
- 在显著白蛋白尿(>300 mg/g)者中加入尿白蛋白肌酐比校准显著改善,校准斜率1.05(0.84-1.20)对比1.39(1.14-1.65),P=0.01。
关键数值与推荐
- 预测因子包括吸烟状态、收缩压、胆固醇、降压或他汀使用、糖尿病及估算肾小球滤过率。
临床怎么用
- 可用于无已知心血管病的30至79岁成人进行绝对风险分层,指导一级预防决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD. METHODS: The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets. RESULTS: Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65]; P=0.01). CONCLUSIONS: PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.
引用
- Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2023. PMID: 37947085. doi:10.1161/CIRCULATIONAHA.123.067626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。